Anson Funds Management LP Tcr2 Therapeutics Inc. Transaction History

Anson Funds Management LP

  • $839 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022
SELL
$2.4 - $4.71 $244,413 - $479,661
-101,839 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$4.58 - $8.34 $466,422 - $849,337
101,839 New
101,839 $475,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Anson Funds Management LP Portfolio

Follow Anson Funds Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anson Funds Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Anson Funds Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email